174 related articles for article (PubMed ID: 38395765)
1. Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients.
Wang M; Tang S; Li G; Huang Z; Mo S; Yang K; Chen J; Du B; Xu J; Ding Z; Dong F
BMC Gastroenterol; 2024 Feb; 24(1):81. PubMed ID: 38395765
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study.
Jiang M; Zhang X; Wu X; Xu Z; Pan J; He H; Luo Y; Chen J
Ann Transl Med; 2023 Jan; 11(2):38. PubMed ID: 36819532
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.
Bende F; Sporea I; Șirli R; Bâldea V; Lazăr A; Lupușoru R; Fofiu R; Popescu A
Med Ultrason; 2021 Feb; 23(1):7-14. PubMed ID: 33220028
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease.
Kuroda H; Abe T; Fujiwara Y; Nagasawa T; Takikawa Y
J Med Ultrason (2001); 2021 Oct; 48(4):471-480. PubMed ID: 34415481
[TBL] [Abstract][Full Text] [Related]
5. A Comparative Study of Ultrasound Attenuation Imaging, Controlled Attenuation Parameters, and Magnetic Resonance Spectroscopy for the Detection of Hepatic Steatosis.
Bao J; Lv Y; Wang K; Wang Q; Chen Y; Dong Y; Zhu Y; Wang W
J Ultrasound Med; 2023 Jul; 42(7):1481-1489. PubMed ID: 36583414
[TBL] [Abstract][Full Text] [Related]
6. Correlation and Performance of three Ultrasound Techniques to Stage Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.
Shen Q; Hao Y; Chen J; Liu Q; Jia H; Liu L
Curr Med Imaging; 2024; 20():1-12. PubMed ID: 38389362
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Diagnosis of Nonalcoholic Fatty Liver Disease with Ultrasound Attenuation Imaging in a Biopsy-Proven Cohort.
Huang YL; Bian H; Zhu YL; Yan HM; Wang WP; Xia MF; Dong Y; Gao X
Acad Radiol; 2023 Sep; 30 Suppl 1():S155-S163. PubMed ID: 37407373
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases.
Ni XX; Lian M; Wu HM; Li XY; Sheng L; Bao H; Miao Q; Xiao X; Guo CJ; Li H; Ma X; Hua J
World J Gastroenterol; 2021 Jan; 27(1):80-91. PubMed ID: 33505152
[TBL] [Abstract][Full Text] [Related]
9. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy and Optimal Cut-off of Controlled Attenuation Parameter for the Detection of Hepatic Steatosis in Indian Population.
Kuchay MS; Choudhary NS; Sharma D; Krishan S; Mishra SK; Wasir JS; Singh MK; Saraf N; Dhampalwar S; Sud R
J Clin Exp Hepatol; 2022; 12(3):893-898. PubMed ID: 35677514
[TBL] [Abstract][Full Text] [Related]
12. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
13. [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease].
Hou MM; Yuan XW; Wang YQ; Zhang Y; Zhang SY; Yu SH; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):290-296. PubMed ID: 35462485
[No Abstract] [Full Text] [Related]
14. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Pu K; Wang Y; Bai S; Wei H; Zhou Y; Fan J; Qiao L
BMC Gastroenterol; 2019 Apr; 19(1):51. PubMed ID: 30961539
[TBL] [Abstract][Full Text] [Related]
15. Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis.
Semmler G; Wöran K; Scheiner B; Unger LW; Paternostro R; Stift J; Schwabl P; Bucsics T; Bauer D; Simbrunner B; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
United European Gastroenterol J; 2020 Apr; 8(3):321-331. PubMed ID: 32213023
[TBL] [Abstract][Full Text] [Related]
16. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.
Thiele M; Rausch V; Fluhr G; Kjærgaard M; Piecha F; Mueller J; Straub BK; Lupșor-Platon M; De-Ledinghen V; Seitz HK; Detlefsen S; Madsen B; Krag A; Mueller S
J Hepatol; 2018 May; 68(5):1025-1032. PubMed ID: 29343427
[TBL] [Abstract][Full Text] [Related]
17. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
18. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
Caussy C; Alquiraish MH; Nguyen P; Hernandez C; Cepin S; Fortney LE; Ajmera V; Bettencourt R; Collier S; Hooker J; Sy E; Rizo E; Richards L; Sirlin CB; Loomba R
Hepatology; 2018 Apr; 67(4):1348-1359. PubMed ID: 29108123
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
20. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
